Start-up
Falls in older persons with HIV: Frequency, risk factors and feasibility of a future interventional trial
Learn MoreCompleted
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
Learn MoreOngoing
A learning health system to improve care in people living with HIV
Learn MoreOngoing
Perception of menopausal hormone therapy amongst women living with HIV: A feasibility study for a future randomized controlled trial
Learn MoreOngoing
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
Learn MoreEnrolling
The role of female sex hormones and chronic/latent co-infections on cellular aging and comorbidities in women living with HIV
Learn MoreOngoing
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Learn MoreEnrolling
Completed
BonE health in ageING Women: improvement or prevention of changes in bone mineral density by switching antiretroviral agents
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
